# Opdivo (nivolumab)

Type: Product

Source: GetYourBrief — https://getyourbrief.com/entity/opdivo-nivolumab
Canonical HTML page: https://getyourbrief.com/entity/opdivo-nivolumab

## Recent coverage (2 stories, network-wide)

### Oncologists Worldwide Cut Opdivo Doses by up to 92%, Defying FDA's 1-Year Rule
2026-08-20 09:12:50 · Sector: health · Sentiment: Negative · Impact: 7/10 · Sources: 2

A growing movement of oncologists is testing lower or shorter courses of checkpoint inhibitors like Opdivo and Keytruda, challenging the FDA's fixed one-year protocol. For health systems, this raises urgent questions about clinical decision support, patient safety, and value-based oncology as real-world evidence mounts.
Full story: https://gethealthbrief.com/story/fda-cancer-drug-dosing-challenge-health-systems

### Opdivo's 1/12th Dose Shows Efficacy in Indian Study, Sparking FDA Label Debate
2026-08-20 09:12:41 · Sector: bio · Sentiment: Negative · Impact: 7/10 · Sources: 2

Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Full story: https://getbiobrief.com/story/biotech-cancer-drug-dosing-challenge-keytruda-opdivo

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.